

































method.	Moreover,	 the	antibacterial	and	antifungal	activities	were	evaluated	 for	 five	 ligands
and	 their	 complexes.	 The	 computational	 study	 for	 prediction	 of	 absorption,	 distribution,













In	 recent	 years,	 many	 researches	 have	 focused	 on	
exploring	 interaction	of	small	molecules	with	DNA	[1,2].	DNA	
is	 generally	 the	 primary	 intracellular	 target	 of	 anticancer	
drugs,	 so	 the	 interaction	 between	 small	 molecules	 and	 DNA	
can	cause	DNA	damage	in	cancer	cells,	blocking	the	division	of	
cancer	 cells,	 and	 resulting	 in	 cell	 death	 [3,4].	 Drug‐DNA	
interactions	 can	 be	 classified	 into	 two	 major	 categories,	
intercalation	 and	 groove	 binding.	 Intercalation	 involves	 the	
insertion	of	a	planar	molecule	between	DNA	base	pairs,	which	
results	in	a	decrease	in	the	DNA	helical	twist	and	lengthening	
of	 DNA	 [5].	 Groove	 binding,	 unlike	 intercalation,	 does	 not	
induce	 large	 conformational	 changes	 in	 DNA	 and	 may	 be	
considered	similar	to	standard	lock‐and‐key	models	for	ligand‐
macromolecular	 binding	 [6].	 Interestingly,	 the	 correlation	
between	 DNA‐binding	 and	 cytotoxic	 activity	 against	 cancer	
cells	 is	 still	 a	 crucial	 step	 in	 the	 search	 for	 new	 anticancer	
drugs	[7‐10].	The	only	limitation	to	their	application	as	drugs	
could	 stem	 from	 the	 lower	 thermodynamic	 and/or	 kinetic	
stability	of	their	metal	complexes	used	as	drugs	[11]	compared	
with	 the	 analogous	 ruthenium(II)	 or	 platinum(II)	 partners	
[12].	However,	 this	may	be	depending	strongly	on	 the	nature	
of	the	coordinating	ligands.	Among	the	metal	ions	regarded	as	
coordination	 centers	 of	 potential	 anticancer	 agents,	 platinum	
and	 ruthenium	 ions	 are	 the	 most	 widely	 investigated	 up	 to	
now	 [13,14].	 However,	 there	 is	 a	 growing	 interest	 in	 the	
synthesis	 of	 cheaper	 first‐row	 transition	metal	 complexes	 as	
efficient	DNA	binders	with	potential	cytotoxic	activity	[15,16].	
These	metal	 ions	 are	 nowadays	 present	 in	 several	 inorganic	
pharmaceuticals	 used	 as	 drugs	 against	 a	 variety	 of	 diseases,	
ranging	 from	 antibacterial	 and	 antifungal	 to	 anticancer	
applications	[17‐19].	 In	the	 literature,	diverse	zinc	complexes	
with	 biological	 activity	 are	 reported;	 among	 them	 zinc	
complexes	 with	 drugs	 used	 for	 the	 treatment	 of	 Alzheimer	
disease	 [20].	 Other	 complexes	 showed	 antibacterial	 [21],	
antidiabetic	 [22],	 anti‐inflammatory	 [23],	 antimicrobial	 [24]	
and	antiproliferative‐antitumor	activities	[25,26].	A	number	of	
zinc	metal	 complexes	 have	 been	 synthesized	 and	 studied	 for	
their	 bioactivity	 [27,28].	 Especially,	 binding	 of	 zinc(II)	
complexes	 to	 DNA	 has	 attracted	 much	 attention	 [29,30].	
Nitrogen	 ligands	 have	 been	 extensively	 used	 in	 coordination	











In	 this	 study,	 a	 series	 of	 Zn(II)	 complexes	 of	 sulfadiazine	
with	 different	 amino	 acid	 has	 been	 synthesized	 and	 charac‐
terized.	 The	 prepared	 complexes	 were	 used	 to	 investigate	
















the	 ligand	 was	 recorded	 on	 a	 Shimadzu	 GC‐S‐QP	 1000	 EX	
spectrometer	 using	 a	 direct	 inlet	 system.	 Thermal	 analysis	
measurements	 (TGA,	 DTA)	 were	 recorded	 on	 a	 Shimadzu	






Sulfadiazine,	 DL‐Methionine,	 L‐	 Cystine,	 DL‐Valine,	 DL‐
leucine,	 DL‐Serine,	 N,Nʹ‐dicyclohexyl	 carbodiimide,	 zinc	
chloride,	 9H‐fluoren‐9‐ylmethoxycarbonyl	 (FMOC)	 and	 DNA	





A	 mixture	 of	 sulfadiazine	 (0.01	 mole)	 and	 0.01	 mole	 of	
FMOC‐amino	 acid	 was	 dissolved	 in	 40	 mL	 tetrahydrofuran	
(Scheme	1).	The	mixture	was	cooled	to	0	°C,	then	2.06	g	(0.01	
mole)	N,Nʹ‐dicyclohexyl	 carbodiimide	 (DCCD)	dissolved	 in	10	
mL	 tetra‐hydrofuran	 was	 added.	 The	 reaction	 mixture	 was	
stirred	for		3‐5	h	at	0	°C,	then	allowed	to	stand	for	24	h	at	room	
temperature.	 A	 few	 drops	 of	 acetic	 acid	was	 added,	 then	 the	
precipitate	 of	 N,Nʹ‐dicyclohexylurea	 was	 filtered	 off.	 The	
filtrate	was	 concentrated	 in	vacuum	 to	dryness.	 The	 residual	
material	was	 recrystallized	 from	ethanol‐water,	 and	obtained	
in75‐80	 %	 yield.	 The	 amino	 acid‐sulfadiazine	 ligands	 were	
chromatographically	 homogenous	 when	 developed	 with	
iodine	solution‐benzidine	and	gave	negative	ninhydrin	test.	
2‐Amino‐3‐methyl‐N‐(4‐(N‐(pyrimidin‐2‐yl)sulfamoyl)	
phenyl)butanamide	 (VS):	 Yield:	 79%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3340,	 3200	 (NH2),	 3038	 (NH),	 2934	 (CH‐Arom),	 1640	 (CO),	
1587	(CN),	1496	(NH2),	1442	(SO2).	1H	NMR	(300	MHz,	DMSO‐
d6,	δ,	ppm):	11.48	(b,	s,	2H,	NH2),	8.45	(s,	1H,	NH	NHCO),	8.31	
(s,	 2H,	 2CH‐Pyrimidin),	 7.62‐6.50	 (m,	 5H,	 Ar‐H	 (4H)	 +	 CH‐
Pyrimidin	 (1H)),	 5.74	 (s,	 1H,	 NHSO2),	 3.33‐2.40	 (m,	 8H,	
Aliphatic).	 Anal.	 calcd.	 for	 C15H19N5O3S:	 C,	 51.56;	 H,	 5.48;	 N,	
20.04.	Found:	C,	51.50;	H,	5.40;	N,	20.07%.	
2‐Amino‐4‐methyl‐N‐(4‐(N‐(pyrimidin‐2‐yl)sulfamoyl)	
phenyl)pentanamide	 (LS):	 Yield:	 80%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3354,	 3236	 (NH2),	 3038	 (NH),	 2948	 (CH‐Arom),	 1652	 (CO),	
1586	(CN),	1496	(NH2),	1442	(SO2).	1H	NMR	(300	MHz,	DMSO‐
d6,	δ,	ppm):	10.56	(b,	s,	2H,	NH2),	8.45	(s,	1H,	NH	NHCO),	8.31	
(s,	 2H,	 2CH‐pyrimidin),	 7.64‐6.45	 (m,	 5H,	 Ar‐H	 (4H)	 +	 CH‐
pyrimidin	 (1H)),	 5.05	 (s,	 1H,	 NHSO2),	 3.33‐2.49	 (m,	 10H,	
Aliphatic).	 Anal.	 calcd.	 for	 C16H21N5O3S:	 C,	 52.88;	 H,	 5.82;	 N	
19.27.	Found:	C,	52.89;	H,	5.84;	N,	19.30%.	
2‐Amino‐3‐hydroxy‐N‐(4‐(N‐(pyrimidin‐2‐yl)sulfamoyl)	
phenyl)propanamide	 (SS):	 Yield:	 78%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3354,	 3244	 (NH2),	 3038	 (NH),	 2936	 (CH‐Arom),	 1648	 (CO),	
1587	(CN),	1496	(NH2),	1442	(SO2),	3500	(OH).	1H	NMR	(300	
MHz,	DMSO‐d6,	δ,	ppm):	11.42	(b,	s,	2H,	NH2),	8.47	(s,	1H,	NH	
NHCO),	 8.33	 (s,	 2H,	 2CH‐pyrimidin),	 7.59‐6.48	 (m,	 5H,	 Ar‐H	
(4H)	 +	 CH‐pyrimidin	 (1H)),	 5.69	 (s,	 1H,	 NHSO2),	 4.62	 (s,	 1H,	
OH‐Ser),	 3.33	 (bs,	 1H,	 CH‐Ser),	 2.51	 (s,	 2H,	 CH2‐Ser).	 Anal.	
calcd.	 for	 C13H15N5O4S:	 C,	 46.28;	 H,	 4.48;	 N,	 20.76.	 Found:	 C,	
46.21;	H,	4.56;	N,	20.80%.	
2‐Amino‐3‐mercapto‐N‐(4‐(N‐(pyrimidin‐2‐yl)sulfamoyl)	
phenyl)propanamide	 (CS):	 Yield:	 82%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3380,	 3225	 (NH2),	 3036	 (NH),	 2950	 (CH‐Arom),	 1650	 (CO),	
1596	(CN),	1496	(NH2),	1440	(SO2),	2650	(SH).	 1H	NMR	(300	
MHz,	DMSO‐d6,	δ,	ppm):	11.26	(b,	s,	2H,	NH2),	8.48	(s,	1H,	NH	
NHCO),	 8.37	 (s,	 2H,	 2CH‐pyrimidin),	 7.96‐6.55	 (m,	 5H,	 Ar‐H	
(4H)	 +	 CH‐pyrimidin	 (1H)),	 6.00	 (s,	 1H,	 NHSO2),	 2.88	 (s,	 1H,	
CH‐CS),	2.73	(s,	2H,	CH2‐CS),	2.08	(s,	1H,	SH‐CS).	Anal.	calcd.	for	
C13H15N5O3S2:	 C,	 44.18;	H,	 4.28;	N,	 19.82.	 Found:	 C,	 44.15;	H,	
4.30;	N,	19.84%.	
2‐Amino‐4‐(methylthio)‐N‐(4‐(N‐(pyrimidin‐2‐yl)sulfamoyl)	
phenyl)butanamide	 (MS):	 Yield:	 85%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3348,	 3256	 (NH2),	 3086	 (NH),	 2936	 (CH‐Arom),	 2872	 (CH‐
Aliphatic),	 1650	 (CO),	 1586	 (CN),	 1496	 (NH2)	1440	 (SO2).	 1H	
NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	11.11	(b,	s,	2H,	NH2),	8.48	







Zinc	 (II)	 chloride	 (0.01	 mole)	 was	 dissolved	 in	 40	 mL	
ethanol,	 then	 added	 to	 0.01	 mole	 of	 the	 prepared	 ligand	







Compound	 TPSA	 %ABS	 CLogP	 LogS	 MW	 nON	 nOHNH	 Lip‐V.	 Volume	A3	 E	gap.	 Mr	
D  
20 	
L‐VS	 127.07	 65.16	 0.04	 ‐2.56 349.42 8 4 0 300.43 ‐8.65	 90.79 +33.5
L‐LS	 127.07	 65.16	 0.57	 ‐4.00 363.44 8 4 0 317.23 ‐8.71	 101.46 +38
L‐SS	 147.30	 58.18	 ‐0.74	 ‐2.24 337.36 9 5 0 275.29 ‐8.75	 89.09 +20
L‐CS	 127.07	 65.16	 0.75	 ‐3.43 353.42 8 4 0 284.94 ‐8.87	 95.57 +28
L‐MS	 127.07	 65.16	 0.28	 ‐3.64 381.48 8 4 0 318.77 ‐8.18	 105.01 +42
*	 TPSA:	 Total	 Polar	 surface	 area,	%ABS:	 109‐0.345	 *	 TPSA,	 C	 Log	 P:	 Calculated	 lipophilicity,	 Log	 S:	 Solubility	 parameter,	 nON:	 Number	 of	 hydrogen	 bond	







3352,	 3250	 (NH2),	 3038	 (NH),	 2940	 (CH‐Arom.),	 1650	 (CO),	
1586	(CN),	1490	(NH2),	1442	(SO2).	1H	NMR	(300	MHz,	DMSO‐
d6,	δ,	ppm):	11.50	(b,	s,	2H,	NH2),	8.48	(s,	1H,	NH	NHCO),	8.33	
(s,	 2H,	 2CH‐pyrimidin),	 7.60‐6.49	 (m,	 5H,	 ArH	 (4H)	 +	 CH‐
pyrimidin	 (1H)),	 5.74	 (s,	 1H,	 NHSO2),	 3.33‐2.40	 (m,	 8H,	
Aliphatic	protons).	Anal.	calcd.	for	C15H25N5O7SZn:	C,	37.16;	H,	
5.16;	N,	14.45.	Found:	C,	37.10;	H,	5.20;	N,	14.41%.	
ZnII‐LS,	Zn(LS)(OH)2.H2O:	 Yield:	 75%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3342,	 3254	 (NH2),	 3038	 (NH),	 2942	 (CH‐Arom),	 1635	 (CO),	
1588	(CN),	1490	(NH2),	1440	(SO2).	1H	NMR	(300	MHz,	DMSO‐
d6,	δ,	ppm):	10.56	(b,	s,	2H,	NH2),	8.47	(s,	1H,	NH	NHCO),	8.30	
(s,	 2H,	 2CH‐pyrimidin),	 7.70‐6.47	 (m,	 5H,	 ArH	 (4H)	 +	 CH‐
pyrimidin	 (1H)),	 5.05	 (s,	 1H,	 NHSO2),	 3.33‐2.49	 (m,	 10H,	
Aliphatic	protons).	Anal.	calcd.	for	C16H25N5O6S2Zn:	C,	39.96;	H,	
5.20;	N,	14.57.	Found:	C,	40.00;	H,	5.23;	N,	14.59%.	
ZnII‐SS,	 Zn(SS‐H)(OH)2.0.5H2O:	 Yield:	 73%.	 FT‐IR	 (KBr,	 ν,	




pyrimidin	 (1H)),	 5.69	 (s,	 1H,	NHSO2),	 3.33	 (b,	 s,	 1H,	 CH‐Ser),	
2.51	(s,	2H,	CH2‐Ser).	Anal.	calcd.	for	C13H17N5O6.5SZn:	C,	36.59;	
H,	4.35;	N,	15.23.	Found:	C,	36.58;	H,	4.35;	N,	15.22%.	
ZnII‐CS,	 Zn(CS‐H)2.H2O:	 Yield:	 77%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
3350,	 3262	 (NH2),	 3038	 (NH),	 2944	 (CH‐Arom),	 1650	 (CO),	
1586	(CN),	1490	(NH2),	1440	(SO2).	1H	NMR	(300	MHz,	DMSO‐
d6,	δ,	ppm):	11.38	(b,	s,	4H,	NH2),	8.49	(s,	2H,	NH	NHCO),	8.40	
(s,	 4H,	 2CH‐pyrimidin),	 7.61‐6.51	 (m,	 10H,	 ArH	 (8H)	 +	 CH‐
pyrimidin	(2H)),	5.93	(s,	2H,	NHSO2),	2.78	(s,	2H,	CH‐CS),	2.66	
(s,	 4H,	 CH2‐CS).	 Anal.	 calcd.	 for	 C26H30N10O7S4Zn:	 C,	 39.62;	H,	
3.81;	N,	17.78.	Found:	C,	39.66;	H,	3.84;	N,	17.76%.	
ZnII‐MS,	Zn(MS)(OH)2	.H2O:	Yield:	79%.	FT‐IR	(KBr,	ν,	cm‐1):	
3314,	 3266	 (NH2),	 3088	 (NH),	 2936	 (CH‐Arom),	 2872	 (CH‐
Aliphatic),	 1638	 (CO),	 1586	 (CN),	 1490	 (NH2)	1442	 (SO2).	 1H	
NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	11.40	(b,	s,	2H,	NH2),	8.48	
(s,	1H,	NH	NHCO),	8.37	 (s,	 2H,	2CH‐pyrimidin),	7.61‐6.50	 (m,	
5H,	ArH	(4H)	+	CH‐pyrimidin	(1H)),	5.89	(s,	1H,	NHSO2),	3.42‐










A	 fixed	 amount	 of	 the	 ligand	 (5	 mg/mL	 in	 methanol)	 is	
spotted	on	the	RP‐18	TLC	plates	[35],	followed	by	addition	of	
known	amount	of	DNA	(1	mg/mL	 in	methanol:water	mixture	
(8:2,	 v:v))	 on	 the	 same	 spot.	 Daunomycin	 was	 used	 as	 a	
positive	 control.	 After	 complete	 spotting,	 the	 plates	 were	
developed	 with	 the	 same	 solvent	 system.	 The	 position	 of	
unbounded	 DNA	 was	 visualized	 by	 spraying	 the	 plates	 with	






DNA/methyl	 green	 complex	 (20	 mg)	 was	 suspended	 in	
100	mL	of	0.05	M	tris‐HCl	buffer	(pH	=	7.5)	containing	7.5	mM	
MgSO4	 and	 stirred	 at	 37	 °C	with	 a	magnetic	 stirrer	 for	 24	 h	
[36].	 The	 calculated	 amounts	 of	 samples	 were	 placed	 in	










The	 anti‐bacterial	 activity	 of	 the	 synthesized	 compounds	
was	 tested	 against	 two	 Gram‐negative	 bacteria:	 Escherichia	
coli	(NCTC	10416),	Pseudomonas	aeruginosa	(NCIB	9016),	and	
two	 Gram‐positive	 bacteria:	 Bacillus	 subtilis	 (NCIB	 3610),	
Staphylococcus	aureus	(NCTC	7447),	and	fungi	namely	Candida	





The	 synthesized	 L‐amino	 acids	 sulfadiazine	 ligands	 and	
their	 corresponding	 complexes	were	 tested	 for	 their	 in	 vitro	
antibacterial	 activity	 by	 using	 paper	 disc	 diffusion	 technique	
[37,38].	 The	 sterilized	 (autoclaved	 at	 120	 °C	 for	 30	 min)	
medium	(40‐50	°C)	was	incubated	(1	mL/100	mL	of	medium)	
with	 the	 suspension	 (105	 cfu/mL)	 of	 the	 micro‐organism	
(matched	to	McFarland	barium	sulphate	standard)	and	poured	
into	 a	 petridish	 to	 give	 a	 depth	 of	 3‐4	 mm.	 The	 paper	
impregnated	with	the	tested	compounds	(µg/mL	in	methanol)	
was	 placed	 on	 the	 solidified	 medium.	 The	 plates	 were	 pre‐
incubated	for	1	h	at	room	temperature	and	incubated	at	37	°C	
for	 24	 and	 48	 h	 for	 anti‐bacterial	 and	 anti‐fungal	 activities,	
respectively.	Ampicillin	(mg/disc)	was	used	as	a	standard	for	






was	 determined	 by	 agar	 streak	 dilution	 method.	 A	 stock	
solution	 of	 the	 synthesized	 compound	 (100	 µg/mL)	 in	







was	 prepared	 to	 contain	 approximately	 (105	 cfu/mL)	 and	
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of	 Molecular	 Operating	 Environment	 (MOE).	 Optimization	
Conformational	 analyses	 of	 the	 built	 molecules	 were	
performed	 in	 a	 two‐step	 procedure.	 First,	 these	 compounds	
were	 submitted	 to	 energy	 minimization	 tool	 using	 the	
included	 MOPAC	 7.0.	 The	 geometry	 of	 the	 compounds	 was	
optimized	 using	 the	 semi‐empirical	 AM1	 Hamiltonian	 with	
Restricted	 Hartree‐Fock	 (RHF)	 and	 RMS	 gradient	 of	 0.05	
Kcal/mol.	 Then,	 the	 obtained	model	was	 implemented	 to	 the	
‘Systematic	Conformational	Search’	of	the	MOE.	All	items	were	
set	 as	 default	 with	 RMS	 gradient	 of	 0.01	 Kcal/mol	 and	 RMS	





The	 crystal	 structure	 of	 the	 [d(CGCAAATTTGCG)]2	with	 a	
distamycin	 molecule	 was	 used	 for	 the	 receptor	 molecule,	
water	 and	 distamycin	 molecules	 around	 the	 duplex	 were	
removed,	 then	 hydrogen	 atoms	were	 added.	 The	 parameters	
and	 charges	 were	 assigned	 with	 MMFF94x	 force	 field.	 After	
alpha‐site	 spheres	 were	 generated	 using	 the	 SITE	 FINDER	










N	 terminus	 of	 a	 peptide	 chain	 by	 acidolysis	 using	 trifluoro‐




cm‐1	 attributed	 to	 νNH2.	 The	 IR	 spectra	 also	 show	 band	 at	
1640‐1652	 cm‐1	 corresponding	 to	 νCO,	 at	 the	 same	 time	 the	
band	 attributed	 to	 ν(O=S=O)	 is	 appearing	 around	 1440	 cm‐1	
[41,42].	 The	 band	 at	 3500	 cm‐1	 in	 the	 SS	 spectrum	 is	
corresponding	to	νOH.	1H	NMR	spectra	of	CS	and	SS	ligands	in	
dimethyl‐sulfoxide‐d6	 exhibited	 signals	 at	 δ	 11.26	 and	 11.42	
ppm,	 respectively,	 assigned	 to	 2H,	 NH2.	 L‐Cystinoyl	 sulfadi‐
azine	 shows	 a	 signal	 at	 δ	 2.08	 ppm	 assigned	 to	 1H,	 SH,	
whereas	the	spectrum	of	DL‐Serinoyl	sulfadiazine,	(SS)	shows	
a	 signal	 at	 δ	 4.62	 ppm	 assigned	 to	 1H,	 OH.	 The	 mass	
spectroscopy	shows	molecular	ion	peak	at	381,	353,	349,	351	
and	363	for	MS,	CS,	VS,	SS	and	LS,	respectively.	The	IR,	1H	NMR	
and	 mass	 spectroscopy	 together	 with	 %C,	 %H	 and	 %N	





In	order	 to	 investigate	 the	mode	of	binding	of	zinc	 ion	 to	
the	 organic	 ligands,	 the	 IR	 spectral	 data	 of	 the	 prepared	
ligands	were	compared	to	that	of	the	zinc	complexes.	In	case	of	
Zn(II)	complexes	of	MS,	VS	and	LS	ligands,	the	mode	of	binding	
was	 found	 to	 be	 coordination	 of	 the	 ligands	 to	 the	 zinc	 ion	
through	carbonyl	oxygen	and	nitrogen	atom	of	the	NH2	group.	
This	 assumption	was	 supported	 by	 the	 observed	 IR	 spectral	
data.	 The	bands	 attributed	 to	 ν(NH2)	 in	 the	 IR	 spectra	 of	 the	
Zn(II)	 complexes	were	 shifted	 to	 3314‐3352	 and	 3200‐3266	
cm‐1.	The	carbonyl	band	ν(C=O)	which	appears	at	1640‐1652	
cm‐1	in	ligands	spectra	was	shifted	to	lower	wavenumber	with	
smaller	 intensities	 than	 that	 of	 the	 free	 ligands.	 The	 bands	
assigned	 to	 ν(O=S=O),	 ν(CN)	 and	 ν(NH)	 appear	 at	 the	 same	
position	 in	 the	 Zn(II)	 complexes	 spectra	 with	 no	 change	
representing	 no	 participation	 in	 the	 coordination.	 The	 IR	
spectral	data	for	ZnII‐CS	represents	that	the	Zn	ion	binds	to	CS	
through	 SH	 group	 with	 displacement	 of	 its	 proton	 and	 NH2	
nitrogen	 atom.	 This	 mode	 of	 binding	 is	 supported	 by	
disappearance	 of	 the	 band	 assignable	 to	 SH	 in	 the	 ZnII‐CS	
spectrum	with	shifting	of	the	bands	attributed	to	amino	group	
to	 3350	 and	3262	 cm‐1.	 This	 assumption	 also	was	 supported	
by	disappearing	the	signal	at	δ	2.08	ppm	assigned	to	1H,	SH	in	
the	 1H	 NMR	 spectrum	 of	 the	 ZnII‐CS.	 At	 the	 same	 time,	 by	
comparing	 the	 IR	 spectral	 data	of	 SS	with	 its	Zn(II)	 complex,	
one	 can	 observe	 that	 the	 band	 corresponding	 to	 carbonyl	
ν(C=O)	was	shifted	to	1658	cm‐1	in	the	ZnII‐SS.	The	OH	band	in	
the	 spectrum	 of	 the	 complex	 is	 obscured.	 The	 1H	 NMR	
spectrum	of	ZnII‐SS	reveals	the	disappearance	of	the	signal	at	δ	
4.62	 ppm	 assigned	 to	 1H,	 OH.	 These	 data	 suggest	 that	 the	
Zn(II)	 ion	binds	 to	SS	 through	carbonyl	oxygen	atom	and	OH	
with	 displacement	 of	 its	 proton.	 The	 position	 of	 ν(NH),	
ν(O=S=O)	 and	 ν(NH2)	 bands	 in	 the	 ZnII‐CS	 and	 ZnII‐SS	
complexes	 spectra	 indicate	 that	 theses	 functional	 groups	 do	


















The	 TGA	 thermogram	 confirms	 the	 amount	 of	 solvent	
inside	and/or	outside	the	coordination	sphere	and	gives	some	







corresponds	 to	 removal	 of	 (0.5‐2.0)	 water	 molecule	 with	




and	 ZnII‐SS,	 respectively.	 This	 inflection	 stages	 are	
accompanied	with	weight	 loss	 (calc.	 =	 8.8,	 7.7,	 21.6,	 9.1	 and	
25.1%,	found	=	8.8,	6.7,	20.6,	9.1	and	24.6%)	for	ZnII‐MS,	ZnII‐
CS,	 ZnII‐VS,	 ZnII‐LS	 and	 ZnII‐SS,	 respectively.	 The	 third	 and	
fourth	 stages	 are	 corresponding	 to	degradation	of	 the	 rest	of	
the	complexes	leaving	Zn	oxides	or	carbides	at	the	final	stage.	










       







E	(kJ/mol)	 ∆H	(kJ/mol) ∆S	(J/K.mol) ∆G	(kJ/mol)	
ZnII‐CS	 9.60	/	10.9	 6.82	/	4.02	 ‐21.37	/	‐38.73	 13.96	/	36.40	
ZnII‐MS	 73.03	/	99.03	 70.26	/	92.87	 ‐9.91	/	‐33.05	 73.57	/	119.71	
ZnII‐SS	 40.70	/	134.31	 37.87	/	127.27 ‐35.15	/	‐37.31 49.82	/	158.87	
ZnII‐VS	 3.28	/	131.	 2.45	/	124.08 ‐35.76	/	‐36.92 12.61	/	155.36	









constant,	E	 is	the	activation	energy,	A	 is	constant	and	β	 is	the	
heating	 rate.	 Therefore,	 plotting	  21lnln T
     
	 against	 1/T	
according	 to	equation	(1)	gives	a	straight	 line	whose	slope	 is	
directly	 proportional	 to	 the	 activation	 energy	 (‐E/R).	 The	
activation	entropy	∆S,	the	activation	enthalpy	∆H,	and	the	free	






  	 	 	 	 (2)	
	
H E RT   	 	 	 	 	 (3)	
	
G H T S     	 	 	 	 (4)
		where	 k	 and	 h	 are	 Boltzmann's	 and	 Planck's	 constants,	
respectively,	 T	 is	 the	 temperature	 involved	 in	 the	 calculation	
and	 selected	 as	 the	 peak	 temperature	 of	 Dr‐TGA	 (Figure	 2).	
The	thermodynamic	parameters	for	the	first	and	last	inflection	
points	 were	 calculated	 and	 listed	 in	 Table	 2.	 The	 activation	
energies	 of	 decomposition	were	 found	 to	 be	 in	 the	 range	 of	
3.28‐73.03	and	10.97‐134.31	kJ/mol	for	first	and	last	inflection	
stages,	respectively.	The	high	values	of	the	activation	energies	




indicate	 that	 the	 decomposition	 reactions	 proceed	 with	 a	







section.	 The	 proposed	 structures	 for	 all	 complexes	 are	
represented	 as	 Zn(VS)(OH)2.	 2H2O,	 Zn(LS)(OH)2.	 H2O,	 Zn(SS‐
H)(OH)2.	0.5H2O,	Zn(CS‐H)2H2O	and	Zn(MS)(OH)2.H2O.	
In	 order	 to	 established	 enantiomeric	 purity	 of	 isolated	
compounds,	 specific	 rotation	 values	  20D 	 were	 determined,	




amino	 acids.	 These	 values	 with	 the	 HPLC	 analytical	 data	
revealed	 that	 the	 optical	 purity	 of	 the	 resulting	 compounds	
was	 greater	 than	 98%.	 Thus,	 as	 expected,	 stereochemical	
configuration	 at	 α‐carbon	 atom	 of	 the	 amino	 acid	 was	
practically	 unaffected	 and	 this	 synthetic	 transformation	 from	















The	 small	 molecules	 binding	 with	 DNA	 has	 attracted	




plate	 method,	 after	 developing	 the	 plate,	 the	 position	 of	
unbound	 DNA	 was	 determined	 by	 spraying	 the	 plates	 with	
anisaldehyde	 reagent.	 It	 was	 demonstrated	 that,	 when	 DNA	
was	 mixed	 with	 compounds	 known	 to	 interact	 with	 it,	 e.g.	
ethidium	 bromide,	 the	 complex	 was	 retained	 at	 the	 origin.	
Compounds	with	high	binding	affinity	to	DNA	remained	on	the	
base	 line	 or	 migrated	 for	 a	 very	 short	 distance,	 while	
compounds	with	poor	binding	affinity	did	not	cause	DNA	to	be	
retained	at	the	origin.	
Methyl	 green	 reversibly	 binds	 with	 polymerized	 DNA,	
which	 forming	 a	 stable	 complex	 at	 neutral	 pH	 [36].	 The	






Compound	 IC50	a	 E	Scor	b	 E	c E‐ele	d HF	e HOMO	f	 LUMO	g
ZnII‐VS	 56	 ‐14.30	 ‐127878.53 ‐950772.63 ‐109.53 ‐3.12	 2.19
ZnII‐LS	 55	 ‐4.11	 ‐120459.95 ‐872885.19 ‐39.96 ‐0.02	 3.68
ZnII‐SS	 10	 ‐16.86	 ‐116815.42 ‐769649.5 ‐121.39 ‐9.72	 ‐0.86
ZnII‐CS	 13	 ‐18.83	 ‐196218.89 ‐1753947.1 89.76 2.15	 7.91
ZnII‐MS	 19	 ‐16.50	 ‐121399.88 ‐881978.06 ‐66.22 ‐0.58	 4.55
Dau.	 29	 	 	 	 	
Compound	 E.Gap	h	 Dipole	k	 IP	l E	m E	ele	n E	vdw	p	 	
ZnII‐VS	 ‐5.32	 8.00	 9.72	 ‐153.02	 ‐347.29	 127.72	 	
ZnII‐LS	 ‐3.71	 15.71	 0.02 ‐99.22 ‐218.81 45.92	 	
ZnII‐SS	 ‐8.85	 9.12	 2.25	 ‐60.17	 ‐169.26	 53.39	 	
ZnII‐CS	 ‐5.75	 10.27	 ‐2.15	 66.53	 ‐64.57	 79.29	 	
ZnII‐MS	 ‐5.14	 14.58	 0.58 ‐172.35 ‐365.40 100.85	 	


































This	 colorimetric	 assay	 was	 used	 to	 measure	 the	
displacement	 of	methyl	 green	 from	DNA	 by	 compounds	 that	
having	 the	 ability	 to	 bind	 with	 DNA.	 The	 degree	 of	
displacement	 was	 determined	 spectrophotometrically	 by	
measuring	 the	 change	 in	 the	 initial	 absorbance	 of	 the	 DNA‐
methyl	green	solution	in	the	presence	of	reference	compound.	
Results	 from	 DNA	 binding	 assay	 (Table	 3)	 revealed	 that	 the	













The	 tested	micro‐organism	 strains	used	 in	 this	 study	 are	
Gram‐negative	 bacteria:	 Escherichia	 coli	 (NCTC‐10416),	
Pseudomonas	 aeruginosa	 NCIB9016	 and	 Gram‐positive	
bacteria	 Bacillus	 subtilis	 (NCIB‐3610),	 Staphylococcus	 aureus	
(NCTC‐7447).	 Ampicillin	 was	 used	 as	 standard	 drug.	 The	
results	 of	 antimicrobial	 activity	 taken	 as	 inhibition	 zone	
diameter	 and	minimum	 inhibitory	 concentration	 (MIC)	were	
furnished	in	Table	4.	From	Table	4,	it’s	clearly	that	the	ligands	
SS	and	CS	were	found	to	be	low	to	moderate	active	against	all	
the	 tested	 bacterial	 strains	 with	 MIC	 5	 µg/mL.	 On	 the	 other	
hand	the	ligands	VS,	LS	and	MS	show	no	activity	against	tested	
bacterial	strains.	The	ligand	VS	have	moderate	potency	against	
E.	 coli.	 The	 complexes	 ZnII‐SS	 and	 ZnII‐CS	 have	 high	 potency	
against	all	 the	tested	bacterial	strains	with	MIC	between	1.25	
and	 2.5	 µg/mL	 except	 that	 of	 B.	 subtilis	 which	 has	 been	
affected	 moderately	 by	 these	 two	 complexes.	 Furthermore	
ZnII‐VS,	ZnII‐LS	and	ZnII‐MS	showed	moderate	to	low	activities	
(MIC	=	2.5	and	5	µg/mL)	against	all	tested	bacterial	strain.	The	





In	 vitro	 antifungal	 studies	 of	 all	 synthesized	 ligands	 and	
their	 complexes	were	 tested	against	Candida	albicans	 (IMRU‐
3669)	 and	 Aspergillus	fumigatus	(ATCC‐22019),	 Ampicillin	
was	used	as	reference	drug	and	their	inhibition	zone	diameter	
and	 minimum	 inhibitory	 concentration	 (MIC)	 values	 were	
depicted	in	(Table	4).	In	general,	the	synthesized	L‐amino	acid	
ligands	 VS,	 LS	 and	 MS	 exerted	 inactive	 in	 vitro	 antifungal	
activity	 against	 all	 tested	 organisms.	 The	 ligands	 SS	 and	 CS	
showed	moderated	 activities	with	MIC	 (5	µg/mL).	Moreover,	
the	complexes	ZnII‐VS,	ZnII‐LS,	ZnII‐SS	and	ZnII‐CS	showed	high	
activities	 against	 A.	 fumigatus	 with	 MIC	 (1.25‐5.00	 µg/mL),	
while	the	complex	ZnII‐MS	shows	low	potency,	MIC	(5	µg/mL)	
with	the	same	organism.	Complexes	ZnII‐LS,	ZnII‐SS,	ZnII‐CS	and	
ZnII‐MS	 have	 moderate	 activity	 against	 C.	 albicans	 with	 MIC	
values	(2.5	and	5.0	µg/mL).	At	the	same	time,	the	complex	ZnII‐






Compound	 E	a	 E	ele	b	 HF	c	 HOMO	d	 LUMO	e	 Dipol	e	 IP	g	 E	h	 E	ele	k	 E	vdw	l	
D‐VS	 ‐100805.65	 ‐698814.44	 ‐29.63 ‐9.45 ‐0.74 3.83 9.70 12.08	 ‐54.71	 43.26
L‐VS	 ‐100807.79	 ‐718525.81	 ‐31.67 ‐9.52 ‐0.87 6.64 9.57 5.96	 ‐59.14	 40.15
D‐	LS	 ‐104403.41	 ‐742566	 ‐40.67 ‐9.38 ‐0.65 7.51 9.38 ‐0.88	 ‐59.85	 45.32
L‐LS	 ‐104403.61	 ‐758480	 ‐40.87 ‐9.34 ‐0.63 9.18 9.34 ‐4.44	 ‐61.77	 45.43
D‐	SS	 ‐98109.52	 ‐640661.44	 ‐19.08	 ‐9.43	 ‐0.76	 7.34	 9.54	 ‐2.34	 ‐54.27	 42.03	
L‐SS	 ‐101023.38	 ‐661686.44	 ‐72.45	 ‐9.57	 ‐0.82	 6.29	 9.43	 ‐0.59	 ‐57.48	 40.77	
D‐	CS	 ‐98107.26	 ‐658230.81	 ‐17.05 ‐9.54 ‐0.93 5.08 9.45 0.28	 ‐47.03	 42.08
L‐CS	 ‐101024.77	 ‐665777.75	 ‐71.98	 ‐9.70	 ‐0.83	 7.44	 9.52	 4.43	 ‐50.20	 40.47	
D‐	MS	 ‐105287.09	 ‐723316	 ‐23.29	 ‐8.68	 ‐0.67	 7.26	 8.98	 2.71	 ‐52.87	 42.06	




















Oral	 bioavailability	was	 considered	 playing	 an	 important	
role	for	the	development	of	bioactive	molecules	as	therapeutic	
agents.	 Many	 potential	 therapeutic	 agents	 fail	 to	 reach	 the	
clinic	 because	 of	 ADMET	 (absorption,	 distribution,	 metabo‐
lism,	elimination	and	toxic)	factors.	Therefore,	a	computational	
study	for	prediction	of	ADMET	properties	of	the	molecules	was	
performed	 for	 the	 prepared	 ligands,	 by	 determination	 of	
topological	 polar	 surface	 area	 (TPSA),	 a	 calculated	 percent	
absorption	 (%ABS)	 which	 was	 estimated	 by	 Zhao	 et	 al.	
equation	[52],	and	 ‘‘rule	of	 five’’,	which	have	been	 formulated	
by	Lipinski	[53].	The	"rule	of	five"	established	that	the	chemical	
compound	 could	 be	 developed	 to	 be	 a	 drug,	 if	 no	more	 than	
one	violation	of	the	following	rule:		




iv. Molecular	weight	 <500	 and	molar	 refractivity	 should	
be	between	40‐130.	
In	addition,	the	total	polar	surface	area	(TPSA)	is	another	
key	 property	 linked	 to	 drug	 bioavailability;	 the	 passively	
absorbed	 molecules	 with	 (TPSA	 >	 140)	 have	 low	 oral	
bioavailability	 [54].	 All	 calculation	 descriptors	 were	 perfor‐
med	 using	 MOE	 program	 [55],	 the	 results	 were	 disclosed	 in	
Table	 1.	 Our	 results	 revealed	 that,	 the	 C	 log	 P	 (factor	 of	 the	
lipophilicity	 [56])	 less	 than	 5.0,	 the	 molecular	 weight	 (MW							
<	500),	hydrogen	bond	acceptors	between	8	and	9,	hydrogen	
bond	 donors	 (4	 and	 5)	 and	 molar	 refractivity	 values	
approximately	 between	 90	 and	 105)	 which	 fulfill	 Lipinski’s	
rule.	 Also,	 the	 percent	 absorption	 of	 the	 whole	 synthesized	
ligands	 ranged	 between	 58.1	 and	 65.1%.	 These	 data	 may	






In	 trying	 to	 achieve	 better	 insight	 into	 the	 molecular	
structure	 of	 the	 most	 preferentially	 steroisomer	 forms	 (L	
and/or	 D)	 and	 complexes,	 conformational	 analysis	 of	 the	
target	 compounds	 has	 been	 performed	 using	 the	 MMFF94	
force‐field	[57,58]	(calculations	in	vacuum,	bond	dipole	option	
for	 electrostatics,	 Polake	 Ribiere	 algorithm,	 RMS	 gradient	 of	
0.01	 kcal/mol)	 implemented	 in	 MOE.	 The	 most	 stable	
conformer	was	fully	geometrical	optimized	by	AM1	[59]	semi‐
empirical	 Hamiltonian	 molecular	 orbital	 calculation	 MOPAC	
package.	 Furthermore,	 the	 computed	 molecular	 parameters,	
total	 energy,	 binding	 energy,	 heat	 of	 formation,	 the	 lowest	
occupied	molecular	 orbital	 (LUMO)	 and	 the	highest	 occupied	
molecular	 orbital	 (HOMO)	 energies,	 potential	 energies,	
solvation	 energies,	 Electrostatic	 energies,	 van	 der	 Waals	
energy	 and	 the	 dipole	moment	 for	 studied	 compounds	were	
calculated	 (Table	 3	 and	 5).	 It	 is	 obvious	 that,	 there	 is	 a	
possibility	 of	 existence	 the	 prepared	 ligand	 in	 both	
diteroisomer	 forms	 (Figure	 3).	 The	 calculated	 molecular	
parameters	 have	 been	 used	 to	 investigate	 the	 most	 stable	
isomer	 forms	 of	 the	 prepared	 amino	 acid	 ligands.	 The	 most	
stable	 isomer	 is	 found	 to	be	 the	L	 form	(table	4).	The	results	
obtained	 from	 the	 enhancement	 of	 the	 computed	 energies	 of	
L‐molecular	 skeleton	 form	 and	 the	 optical	 purity	 of	 the	
ligands,	are	 leading	us	 to	neglect	 the	D‐Form.	The	calculation	
results	 showed	 that,	 the	 lowest	 minimization	 energy	








in	 intermolecular	 interactions	[59]	between	 the	HOMO	of	 the	
drug	 with	 the	 LUMO	 of	 the	 receptor	 and	 vice	 versa.	 The	
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the	 drug	 molecule	 lead	 to	 enhancement	 of	 stabilizing	
interactions,	and	hence,	binding	with	the	receptor.		
Table	 3	 and	 5	 showed	 that	 the	 ligands	 (SS	 and	 CS)	 and	
their	 complexes	 (ZnII‐SS	 and	 ZnII‐CS)	 represented	 the	 lowest	
energy	 gap	 ‐8.74,	 ‐8.87,	 ‐8.85	 and	 ‐5.75	 eV,	 respectively.	 The	
three	 dimensional	 structure	 and	 the	 electrostatic	 potential	
map	 (Figure	 4	 and	 5)	were	 analyzed	 to	 identify	 the	 relation	











out.	 Docking	 experiment	 was	 performed	 using	 default	
parameters	 with	 MOE	 [55].	 The	 crystal	 structure	 of	
[d(CGCAAATTTGCG)]2	 with	 distamycin	 (PDB	 ID:	 2DND)	 was	
obtained	 from	 protein	 data	 bank	 PDB	 [60].	 Distamycin	 was	
removed	 from	 the	 crystal	 structure	 before	 DOCKING	
experiment.	 The	 predicted	 top‐ranking	 pose	 with	 lowest	
energy	 of	 complexes,	 was	 applied	 to	 suggesting	 the	 best	
possible	 geometry	 of	 the	 complexes	 inside	 the	 DNA	 double	
helix	 (Table	 3,	 Figure	 6).	 All	 docked	 complexes	 were	
represented	 in	 CPK	 to	 clarify	 the	 binding	 mode	 of	 these	








ii. All	 complexes	 stabilized	 themselves	 in	 the	 binding	
pocket	by	adjusting:	(a)	phenyl	in	plane	with	diazine		
ring	 in	 complexes	 ZnII‐VS	 and	 ZnII‐CS,	 (b)	 diazine		
coplanar	with	phenyl	 ring	 in	 complexes	 ZnII‐SS	 and	
ZnII‐MS,	 (c)	diazine	 	perpendicular	with	phenyl	 ring	
in	ZnII‐LS,	
iii. At	 the	 same	 time	 the	 whole	 complexes	 were	
stabilized	 in	 the	 binding	 pocket	 base	 by	 adjusting	
their	 phenyl	 and	 diazine	 	 rings	 parallel	 with	 DNA	
base	 in	 ZnII‐VS,	 ZnII‐CS	 and	 ZnII‐MS,	 but	 in	 case	 of	
ZnII‐LS	and	ZnII‐SS	diazine		rings	were	perpendicular	
with	DNA	base,	
iv. The	 complexes	 ZnII‐SS,	 ZnII‐CS	 and	 ZnII‐MS	 showed	
lowest	 docking	 energies	 pose	 ‐16.86,	 ‐18.83	 and									
‐16.50	 kcal/mol,	 respectively	 and	 highest	 affinity	
(IC50	=	10,	13	and	19	µg/mL)	for	DNA	(Table	3).	The	






Series	 of	 Zn(II)	 complexes	 have	 been	 prepared	 and	
characterized	 using	 physicochemical	 methods	 such	 as	 IR,	
electronic,	and	NMR	spectroscopy.	The	activation	parameters	
were	 determined	 by	 thermal	 analyses	 calculations.	 The	
prepared	 organic	 compounds	 behave	 as	 bidendtate	 ligands.	
The	 binding	 of	 Zn(II)	 complexes	 as	 small	 molecules	 to	 DNA	
showed	 that	 the	 complexes	 ZnII‐SS,	 ZnII‐CS	 and	 ZnII‐MS	
revealed	 the	highest	binding	affinity	with	 the	 lowest	docking	
energies	pose.	This	efficiency	of	the	binding	mode	may	be	due	
to	 existence	 polarity	 nature	 of	 the	 amino	 acid	 moiety.	 All	
ligands	 and	 Zn(II)	 complexes	 have	 been	 checked	 for	
antibacterial	 and	 antifungal	 activities.	All	 synthesized	 ligands	
in	 this	study	showed	a	good	oral	absorption	as	antimicrobial	
compounds.	 These	 observations	 suggest	 that	 the	 antibiotic	
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